the aid library

LIST OPTIONS

Filter

1375

Sort by:

Direction:

Download (155)

View PDF (1131)

COVID-19 vaccine tracker and landscape
recommended

World Health Organization WHO (2022) C_WHO

The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. The COVID-19 vaccine tracker: Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-... more

Download (178)

View PDF (111)

Frequently Asked Questions (FAQs) about COVID-19 Candidate Vaccines and Access Mechanisms. Version 3, 6 January 2021

Pan American Health Organisation PAHO (2021) C_WHO

Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.

Download (54)

View PDF (445)

Framework for Equitable Allocation of COVID-19 Vaccine

National Academies of Sciences, Engineering, and Medicine (2020) C1

In response to the coronavirus disease 2019 (COVID-19) pandemic and the societal disruption it has brought, national governments and the international community have invested billions of dollars and immense amounts of human resources to develop a safe and effective vaccine in an unprecedented time f... more

Download (52)

View PDF (480)

COVID-19 Vaccine Acceptance

Compass (2021) CC

Social and behavior change (SBC) professionals have often been tasked to find ways to influence knowledge, attitudes, and practices, about vaccines. Now that the COVID-19 vaccines are becoming available worldwide, renewed emphasis and urgency for SBC efforts arise. To that end, WHO has offered thre... more

Download (68)

View PDF (852)

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended

World Health Organization WHO (2021) C_WHO

Over 18 months into the pandemic, WHO continues to conductglobal surveillance of COVID-19as part of activities on preparedness, readiness and response activities. The need for global surveillance of COVID-19 is greater than ever, asthe implementation of vaccination campaigns and the appearance of va... more

Download (97)

View PDF (154)

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19... more

Download (106)

View PDF (181)

Considérations politiques relatives à la mise en oeuvre d’une approche fondée sur les risques pour les voyages internationaux dans le cadre de la COVID-19, 2 juillet 2021

Organisation mondiale de la Santé OMS (2021) C_WHO

Les pays du monde entier sont confrontés à des situations épidémiologiques diverses, et disposent de capacités de réaction différentes et d’un accès inégal aux outils permettant de sauver des vies. L’Organisation mondiale de la Santé (OMS) recommande aux autorités nationales de contin... more

Download (132)

View PDF (150)

Communicating with health workers aboutCOVID-19 vaccination

World Health Organization WHO, Regional Office of Europe (2021) CC

This training module is designed to equip HWs with knowledge and communication skills to build their confidence and support them in their ability to promote acceptance of COVID-19 vaccination among other HWs.

Download (62)

View PDF (483)

Tracking Global COVID-19 Vaccine Equity: An Update

Rouw, A.; J. Kates, A. Wexler, et al. KFF (2021) CC

Sep 22, 2021. In our updated analysis we find that, as of September 9, there continue to be wide disparities in access and at current rates, most low-income countries (LICs) and most countries in Africa will not reach global vaccination targets. We also find that, compared to July, the rate at whic... more

Download (136)

View PDF (158)

A People’s Vaccine for Refugees: Ensuring access to COVID-19 vaccines for refugees and other displaced people

Oxfam (2021) C1

For most people in displacement contexts, there are simply not enough vaccines available in the places where they are hosted: 85% of refugees are hosted in lower- and middle-income countries, while in the first six months of this year 85% of vaccines went to wealthy countries; lower- and middle inco... more

Download (110)

View PDF (140)

COVID-19: Strategic preparedness and response plan for WHO African Region 1 February 2021-31 January 2022 (Update of 16 April 2021)

World Health Organization WHO, Regional Office of Africa; UNICEF (2021) C_WHO

The 2021 COVID-19 Strategic Preparedness and Response Plan (SPRP) for AFR serves as a regional guide for a holistic public health response to COVID‑19 at regional, national and sub-national levels. The 2021 SPRP: 1. Builds upon the lessons learnt from the implementation of the 2020 SPRP and outl... more

Download (92)

View PDF (132)

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Download (66)

View PDF (416)

Disruption in essential health services in Mexico during COVID-19: an interrupted time series analysis of health information system data

Doubova SV, Leslie HH, Kruk ME, et al. BMJ Global Health (2021) CC

INTRODUCTION: The COVID-19 pandemic has disrupted health systems around the world. The objectives of this study are to estimate the overall effect of the pandemic on essential health service use and outcomes in Mexico, describe observed and predicted trends in services over 24 months, and to estimat... more

Download (84)

View PDF (420)

Impact of the COVID-19 pandemic and response on the utilisation of health services in public facilities during the first wave in Kinshasa, the Democratic Republic of the Congo

Hategeka C, Carter SE, Chenge FM, et al. BMJ Global Health (2021) CC

INTRODUCTION: Health service use among the public can decline during outbreaks and had been predicted among low and middle-income countries during the COVID-19 pandemic. In March 2020, the government of the Democratic Republic of the Congo (DRC) started implementing public health measures across Kin... more

Download (183)

View PDF (229)

Global analysis of health care waste in the context of COVID-19

World Health Organization WHO (2022) CC

The COVID-19 pandemic has led to large increases in healthcare waste, straining under resourced healthcare facilities and exacerbating environmental impacts from solid waste. This report quantifies the additional COVID-19 healthcare waste generated, describes current healthcare waste management syst... more

Download (159)

View PDF (179)

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended

World Health Organization WHO (2022) C_WHO

Contact tracing for COVID-19 is the process of identifying, assessing, and managing people who have been exposed to someone who has been infected with the SARS-CoV-2 virus, while quarantine is the separation of contacts from other people after exposure to a probable or confirmed case of SARS-CoV-2 i... more

Download (94)

View PDF (130)

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so... more

Download (92)

View PDF (132)

WHO COVID-19 policy brief: building trust through risk communication and community engagement, 14 September 2022

World Health Organization WHO (2022) C_WHO

The guidance notes describe key actions that policy-makers at national and subnational levels can take in relation to: diagnostic testing for COVID-19, clinical management of COVID-19, meeting targets for vaccination against COVID-19, maintaining infection control measures for COVID-19 in health-car... more

Download (145)

View PDF (156)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

COVID-19 vaccine tracker and landscape recommended

WHO COVID-19 Detailled Surveillance Data Dashboard recommended

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022 recommended

Guidance on administration of COVID-19 vaccine boosters in Africa recommended

COVID-19 vaccine tracker and landscape
recommended

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended